Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other Operating Expenses (2024 - 2025)

Historic Other Operating Expenses for Madrigal Pharmaceuticals (MDGL) over the last 3 years, with Q3 2025 value amounting to $18.1 million.

  • Madrigal Pharmaceuticals' Other Operating Expenses rose 74210.04% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.1 million, marking a year-over-year increase of 116058.11%. This contributed to the annual value of $6.2 million for FY2024, which is N/A changed from last year.
  • Madrigal Pharmaceuticals' Other Operating Expenses amounted to $18.1 million in Q3 2025, which was up 74210.04% from $9.1 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Other Operating Expenses' 5-year high stood at $18.1 million during Q3 2025, with a 5-year trough of $636000.0 in Q2 2024.